Evolut Low Risk TAVR Still Chugging Along, Now Halfway to Trial’s Finish Line

(MedPage Today) — CHICAGO — Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at low surgical risk, with the Evolut Low Risk trial now halfway to its goal of 10-year follow-up.
In…